‘Devastating’: Retired firefighter says he lost most of his retirement savings investing in stocks that were targeted by a famous short-seller
He turned $110K into $190K, then watched his savings vanish after public criticism from from Citron Research’s Andrew Left.
Retired firefighter says he lost most of his savings investing in stocks that were targeted by famous short-seller
He turned $110K into $190K, then watched his savings vanish after public criticism from from Citron Research’s Andrew Left.
Canopy Growth’s Stock Just Dropped — Here’s Why I’m Still Not Buying
For anyone who has observed Canopy Growth (NASDAQ: CGC) during the past few years, it won’t be shocking to learn that the marijuana company’s stock is diving in May. Since the start of the month, it’s …
Auxly Cannabis is still undervalued, this analyst says
Haywood analyst Neal Gilmer maintained a “Buy” rating and $0.25 target on Auxly Cannabis Group (Auxly Cannabis Group Stock Quote, Chart, News, Analysts, Financials TSX:XLY) in a May 14 report after …
Buy this cannabis stock for a double, analyst says
Haywood analyst Neal Gilmer maintained a “Buy” rating and $3.25 target on Organigram Holdings (Organigram Global Stock Quote, Chart, News, Analysts, Financials TSX:OGI) in a M …
CBD Stocks Creating Opportunities – Established (BCCI), (STG), (WEED), (ACRGF), (RLTR), (CBMJ), and Newcomer (VAPR) Lead the Charge
You would have to be living in isolation to have not picked up on the hottest marijuana derivative consumable and therapeutic center isolate CBD. CBD “Cannabidiol” is the non-psychoactive full spectrum derivative of the hemp and marijuana plant largely credited for the majority of the medical beneficial attributes associated with marijuana.
Auxly Cannabis is still undervalued, this analyst says
Haywood analyst Neal Gilmer maintained a “Buy” rating and $0.25 target on Auxly Cannabis Group (Auxly Cannabis Group Stock Quote, Chart, News, Analysts, Financials TSX:XLY) in a May 14 report after …
Buy this cannabis stock for a double, analyst says
Haywood analyst Neal Gilmer maintained a “Buy” rating and $3.25 target on Organigram Holdings (Organigram Global Stock Quote, Chart, News, Analysts, Financials TSX:OGI) in a M …
Is Canopy Growth Stock Finally Setting Up for a Real Turnaround?
Canopy Growth (NASDAQ: CGC) has made considerable efforts to turn itself around. Over the past few years, the Canada-based cannabis company has significantly reduced its outstandi …
Canopy Growth Is One of the Market’s Most Polarizing Stocks: 3 Scenarios for the Next 12 Months
After years of heavy losses and repeated restructurings, Canopy Growth is showing early signs of stabilization.
Here’s why Tilray Brands stock has crashed after cannabis reclassification
Tilray Brands stock price crashed to its lowest level since August last year despite the recent US policy change that opened the door to its expansion in the country. TLRY dropped to $5.6, much lower …
Is Tilray the Best Value Play in the $7.4 Billion Cannabis Beverage Market?
Although cannabis stocks have not performed well over the past five years, there is still some hope left for the industry. According to some projections, the market will continue …
Why Tilray’s Marijuana Rescheduling Sizzle Has Fizzled
Rescheduling does matter greatly. Moving from Schedule I to Schedule III takes marijuana out of the same league as heroin, and places it in the same ca …
Cannabis ETFs: Regulatory Momentum Returns Focus
Cannabis stocks often trade less on traditional fundamentals alone and more on changes in policy. Cannabis ETFs are a narrow but differentiated thematic play on potential regulatory upside.
Forget SNDL: HITI is a Significantly Better Cannabis Stock
Every cannabis trader’s feed is buzzing about SNDL (NASDAQ:SNDL) because the company’s Q1 2026 release on April 28, 2026 delivered a tidy little EPS beat that retail can rally around. The underlying …
Recent Comments